GPBAR1 and Alzheimer disease: The results suggested that INT-777 significantly improved the cognitive deficits, inhibited the upregulation of NF-κB p65, and attenuated neuroinflammatory responses in AD mice, and the results indicated that the GPBAR1 agonist may be a potential target for the treatment of AD [95].